#CureLGMDR1

LGMD2A/R1 Participants Sought for COVID-19 Survey

Coalition to Cure Calpain 3 is sharing the following communication from the University of Rochester regarding a voluntary research survey to be completed by those living with LGMD2A/R1, a form of calpainopathy, or by their caregivers. Study Investigator: Rabi Tawil, MD

LGMD2A/R1 Patient Enrollment Underway for C3-Sponsored Natural History Study

The GRASP-LGMD consortium is currently recruiting for a natural history study for individuals with mutations in CAPN3 (calpain 3). This study will inform the design of future therapeutic trials and a better understanding of the disease. Participants can now enroll at

Organizations team up to urge health officials to prioritize the neuromuscular disease community for COVID-19 vaccine access

As distribution of COVID-19 vaccines begins, the Muscular Dystrophy Association led Coalition to Cure Calpain 3 and 18 other partner organizations in advocating to over 55 states and localities, urging health officials to prioritize access for the neuromuscular disease community.

C3 is Poised to Make a Difference in the Next Ten Years and Beyond

Coalition to Cure Calpain 3 (C3) has made tremendous progress in driving research towards a cure for limb-girdle muscular dystrophy type 2A (LGMD2A/R1) and raising global disease awareness. Over the last 10 weeks of highlights, you have read all the WAYS

C3 is Driving Progress Towards a Cutting-Edge Cure

Coalition to Cure Calpain 3 (C3) is bringing cutting-edge science to drive progress toward a cure for limb-girdle muscular dystrophy type 2A (LGMD2A/R1). Some of our proudest work yet has been to help support and harness incredible new scientific understanding

C3 is Expanding the Field of LGMD2A/R1 Researchers

Coalition to Cure Calpain 3 (C3) is attracting more researchers to study – and ultimately cure – limb-girdle muscular dystrophy 2A (LGMD2A/R1). We have worked tirelessly to bring more scientists, research, and dollars to focus on and unravel our understudied

C3 is Increasing Scientific Collaboration to Fight LGMD2A/R1

Coalition to Cure Calpain 3 (C3) initiates scientific collaboration to bring the best minds together to fight limb-girdle muscular dystrophy type 2A (LGMD2A/R1). Working to cure LGMD2A/R1 requires connecting ideas, scientists, clinicians, patient groups and companies to elevate research to

C3 is Connecting Patients to Clinical Studies

Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) to clinical studies. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness, we

Building the First LGMD2A/R1 Patient Registry

Coalition to Cure Calpain 3 (C3) has launched the first and only limb-girdle muscular dystrophy type 2A (LGMD2A/R1) patient registry. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness,

C3 is connecting patients with one another!

Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) with one another. In celebration of ten years of progress in our mission to fund research for a cure and raise global